Zobrazeno 1 - 10
of 5 363
pro vyhledávání: '"Palbociclib"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Acute kidney injury (AKI) is a common clinical problem, and patients who survive AKI have a high risk of chronic kidney disease (CKD). The acute protective effects of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in AKI have been exami
Externí odkaz:
https://doaj.org/article/57de70f7347b4015a8791234feab1dbf
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Autor:
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5722-5729 (2024)
Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact
Externí odkaz:
https://doaj.org/article/a433ba64f8604e4fafa1869340c79037
Autor:
Takayuki Kobayashi, Meiko Nishimura, Mari Hosonaga, Rika Kizawa, Saori Kawai, Yosuke Aoyama, Yukinori Ozaki, Ippei Fukada, Fumikata Hara, Toshimi Takano, Takayuki Ueno
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Absolute lymphocyte count (ALC) is a predictive and prognostic factor for various tumor types, including breast cancer. Palbociclib is a CDK4/6 inhibitor widely used for the treatment of metastatic estrogen receptor (ER)-positive,
Externí odkaz:
https://doaj.org/article/1e6f7c53792d4145b42f0e111048dcb5
Autor:
Rand K. Jadallah, Ahmed H. Al Sharie, Saja M. Alzghoul, Jawad M. Al-Karaki, Mohammad S. Bani Amer, Tariq H. Rawashdeh, Osama Alshari
Publikováno v:
Radiology Case Reports, Vol 19, Iss 9, Pp 4049-4054 (2024)
The management of advanced metastasized breast cancer (BC) is a clinically challenging entity with a wide spectrum of novel therapeutics being introduced to the market. Such agents have remodeled BC treatment landscape and prolonged patients’ survi
Externí odkaz:
https://doaj.org/article/d6dc1c8484a142c78d3ebc441ef26a5b
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 395-418 (2024)
Abstract Introduction Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain
Externí odkaz:
https://doaj.org/article/d3d5c5d38dd54e5fb401805a467c3fba
Autor:
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhib
Externí odkaz:
https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Hepatocellular carcinoma (HCC) poses a significant clinical challenge, necessitating the integration of immunotherapeutic approaches. Palbociclib, a selective CDK4/6 inhibitor, has demonstrated promising efficacy in preclinical HCC models an
Externí odkaz:
https://doaj.org/article/98910cd9e30942b5a5cfac1927fa60df
Autor:
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Marika Di Dio, Azzurra Zicarelli, Salvatore De Rosis, Anna Maria Miglietta, Carlo Capalbo, Ernestina Marianna De Francesco, Antonino Belfiore, Fedora Grande, Bruno Rizzuti, Maria Antonietta Occhiuzzi, Giancarlo Fortino, Antonella Guzzo, Gianluigi Greco, Marcello Maggiolini, Rosamaria Lappano
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-22 (2024)
Abstract Background The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (B
Externí odkaz:
https://doaj.org/article/953c860ef51d47f89a770236fa68ff4a
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101039- (2024)
Non-small cell lung cancer (NSCLC) patients without targetable driver mutation have limited treatment options. In this study, we aimed to explore a new therapeutic strategy by using established nine patient-derived xenograft (PDX) and two-dimensional
Externí odkaz:
https://doaj.org/article/6530d2e7bdde4015866a68784ef2fa2b